Description:
NSABP Protocol B-40 - Treatment Form for Bevacizumab A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B7D839C-1CA0-14D8-E044-0003BA3F9857
Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B7D839C-1CA0-14D8-E044-0003BA3F9857Keywords:
Versions (3)
- 8/26/12 8/26/12 -
- 1/9/15 1/9/15 - Martin Dugas
- 6/16/15 6/16/15 -
Uploaded on:
August 26, 2012
DOI:
To request one please log in.License :
Creative Commons BY-NC 3.0 LegacyModel comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Breast Cancer NCT00408408 Treatment - NSABP Protocol B-40 - Treatment Form for Bevacizumab - 2511943v1.0
For treatment groups 1B, 2B, and 3B only. This form must be submitted for both the preoperative and postoperative time points.
- StudyEvent: NSABP Protocol B-40 - Treatment Form for Bevacizumab